By serving as an immediate treatment option that reduces addictive drive without precipitating withdrawal symptoms, GLP-1 supported initiation onto buprenorphine and naltrexone may improve success rates by making it easier for patients to reach the short-term withdrawal thresholds required to begin treatment
This delay is intentional, promoting satiety and better blood sugar control, but it can cause common issues like nausea and fullness
The drug is being studied for obesity, type 2 diabetes, cardiovascular disease, sleep apnea, osteoarthritis-related pain, metabolic liver disease, and other obesity-related conditions
doi:10.1016/j.nicl.2023.103503
Good to Know Patch test when adding any new facial cream, especially if using exfoliants or other active products in the same routine
Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway